

Concept Proposal

Supplementing Existing Awards to Capture Transformational and Special Translational Opportunities

Occasionally, unique opportunities arise in which additional funding would allow an ongoing CIRM-funded project to achieve transformational and translational results.

We propose two ways to address these opportunities.

Level 1

Modest supplement, authorized administratively through Prior Approval Request. Maximum increase would be the lesser of 10% of the original award amount, or up to \$1M. Only awarded once during the lifetime of a specific award. May not request until after project has completed first year, and making satisfactory progress. Only available if supplement will allow the grantee to pursue a critical research study based on very exciting new research results that will elevate the significance of the project substantially, or allow the grantee to make use of a specialized resource that was not available when the project began.

Recommendations will be reported to the Board at the next available Board Meeting. Total funds available to be awarded as supplemental funds: limited to \$4 million or Board replenishment by request.

Level 2

There may be exceptional circumstances in supplemental funding will allow a current CIRM project to achieve transformational results -- results that would change the field of stem cell research, or establish proof of concept for a new therapeutic. Maximum increase would be up to \$3 million and no greater than 30% of the original award. The total amount of funds to be limited to \$6 million or Board replenishment by request.

Process:

- The grantee may not submit a request until after project has completed first year, making satisfactory progress.
- Grantee would submit a brief proposal.
- President would have sole discretion to decide whether full application would be permitted.
- Fully documented application, to be reviewed by CDAP for FDA mandated supplementary study for a DT or SP award or GWG recommendation for other supplements; for reviews conducted by CDAP, the President shall

have the final decision; for reviews conducted by the GWG, the ICOC shall have the final decision.